Natera, Inc. (NASDAQ:NTRA) is one of the 8 Best Genomics Stocks to Buy According to Analysts.
On June 5, Goldman Sachs initiated coverage on Natera, Inc. (NASDAQ:NTRA) with a Neutral rating and a $245 price target, noting the firm’s leadership in the molecular residual disease testing market
Analyst Evie Koslosky pointed to “strong” commercial execution and a tumor-informed approach resulting in higher sensitivity. Goldman is expecting clearer operating leverage as the company continues reinvesting in growth. On June 4, Natera, Inc. (NASDAQ:NTRA) announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal cancer.
Under the agreement, Natera said it will examine CLOVER Phase 2 trial samples using its Signatera assay. It will also deliver real-world data insights drawn from a database exceeding 2 million plasma timepoints. Likoper/ CytoDyn CEO Jacob Lalezari said the partnership will generate insights into “ctDNA response kinetics and disease progression.” Natera’s Vice President, Biopharma Data & AI Partnering, Matt Love, added that the platform helps partners “better understand disease biology, treatment response, and patient outcomes.” Natera, Inc. (NASDAQ:NTRA) is a diagnostics company that discovers, develops, and markets genetic testing services.